Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
β
of holders' portfolios
13F filers
0
institutions
52-week range
$0.04 β $0.08
38% from low
Exchange
OTC Link
OS
MEDIPHARM LABS CORP
No one on the platform currently holds MEDIF.
No tracked institution reports a position in MEDIF as of their last filing.
No one on the platform has traded MEDIF yet.
No recent Form 4 filings on EDGAR β either no insider transactions reported recently or this isn't a SEC-registered issuer.
$MEDIF $LABS.TSX And so it begins βΌοΈ No pumpers, real volume. We shall be rewarded β€οΈ
View on StockTwits β$MEDIF very encouraging volumes.
View on StockTwits β$MEDIF im in again was thinking about it last week. I should listen to that little voice.
View on StockTwits β$MEDIF asked AI if they were selling a lot of product in Brazil , https://share.google/aimode/vVYokR4LoTwNxsy61
View on StockTwits β$MEDIF asked AI if Medipharm was selling a lot of new product in Europe. https://share.google/aimode/48mxkJN7Enki5DrjP
View on StockTwits β$MEDIF $LABS.TSX Greg, time to π in those contracts my brother πͺ You slashed expenses and brought us this π close to the edge of profitability β€οΈ Shine like you do π and turn that progress into real dollars π° Respect π
View on StockTwits β$MEDIF One day soon though , this will ignite. π₯ #WatchList #MarkThisPost $LABS.TSX
View on StockTwits β$SNGX volumes coming in now SNGx $RNXP $HCMC $MEDIF
View on StockTwits β$MEDIF good news and this goes down , I'm so sick of the manipulation
View on StockTwits β$MEDIF this company has FDA approval?ΒΏ
View on StockTwits β$LABS.TSX $MEDIF π₯ Without that proxy contest, weβd already be PROFITABLE this quarter! π°π Over $2M spentβ¦ when one simple line couldβve done it: βWeβre about to be profitable.β π Next quarter? π Itβs OUR time. Numbers. Donβt. Lie. #ProfitAhead #RocketMode #NumbersDontLie #InvestorEnergy
View on StockTwits βRecent $TICKER stream from stocktwits.com β refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $28M | -16.8% | $-0.01 | $-0.01β$-0.01 | β | 1 |
| 2027 | $32M | +13.6% | $-0.00 | $-0.00β$-0.00 | β | 1 |
Forward consensus Β· growth is YoY vs the prior fiscal-year estimate Β· Fwd P/E at the current price Β· source: Financial Modeling Prep
Beat consensus in 2 of the last 5 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $-0.00 | $-0.00 | +0.0% |
| 2026-05-12 | $-0.00 | $-0.00 | +41.4% |
| 2026-03-30 | $-0.00 | $-0.00 | -100.6% |
| 2025-11-13 | $-0.00 | $-0.00 | -69.8% |
| 2025-08-14 | $-0.00 | $-0.01 | -505.5% |